eCTD Submission in Singapore: Practical Challenges and Regulatory Considerations for Pharma Companies

---

Key Takeaways

• The electronic Common Technical Document (eCTD) is set to become the preferred format for pharmaceutical applications in Singapore.
• Technical errors such as incorrect metadata or folder naming remain a leading cause of rejection.
• Strong infrastructure, trained staff, and lifecycle management systems are essential to success.
• Different application types (biologics, new drugs, or generics) have unique requirements.
• Early adoption of future eCTD submission standards will give companies a compliance advantage.

Navigating the Shift to eCTD Submissions in Singapore

In Singapore, the eCTD is set to become the preferred standard for regulatory submissions, covering new drug, generic, and biologics licence applications. However, the format demands precision. From incorrect folder names to metadata errors, even minor missteps in meeting eCTD validation criteria can result in rejection, delays, and costly resubmissions.

Below are the key challenges and regulatory considerations that companies must address in order to ensure successful eCTD submissions.

Understanding eCTD Format Requirements

The eCTD format is built on a modular structure (Modules 1–5), where every document must be correctly named, hyperlinked, and formatted according to the Health Sciences Authority’s (HSA) technical guidance. Since validation is automated, even small errors can result in outright rejection. 

Common mistakes include:

• Incorrect folder naming conventions (one of the leading causes of rejection)
• Broken cross-references or missing hyperlinks
• Non-compliant PDF settings

Companies must therefore adopt a detail-focused approach, using pre-validation checks before submission to ensure every sequence passes.

Infrastructure Essentials for Smooth eCTD Submissions

A strong technical foundation is essential for a successful submission. This includes the right publishing tools, secure systems, and personnel who understand both the technology and regulatory requirements.

Key elements to consider include:

• Compliant eCTD software: Use publishing and validation tools that meet international standards and validation criteria set by the HSA.
• System readiness: Ensure hardware compatibility, implement secure data storage, establish backup protocols, and maintain audit trails to protect data integrity.
• Document management systems (DMS): Integrate platforms for version control, permissions, and archiving to avoid errors and duplications.
• Trained personnel: Staff must be trained to operate publishing tools, troubleshoot validation errors, and manage sequence numbering.
  

For companies without in-house expertise, consider engaging a trusted regulatory consultancy with a strong track record in eCTD implementation and familiarity with HSA requirements. With their help, you can ensure accurate, compliant, and timely submissions.

From Approval to Updates: Managing the eCTD Lifecycle

One of the main advantages of the eCTD format is its ability to handle post-approval changes through lifecycle management. Each update is captured as a new sequence, providing regulators with a clear audit trail.

However, challenges arise when companies:

• Misnumber sequences.
• Submit outdated documents during updates.

To avoid these pitfalls, companies should maintain robust version control systems, clearly track which documents are current, and ensure consistency across all modules. Strong lifecycle management prevents unnecessary resubmissions and supports long-term regulatory compliance.

HSA’s Review Process and Common Queries

Once a dossier passes technical validation, the HSA focuses on scientific and regulatory review. Precision is expected, not only in dossier content but also in how companies respond to deficiency letters.

Best practices include:

• Responding to deficiency letters within the HSA’s stipulated timelines.
• Maintaining an internal log of queries for future submissions.
• Keeping responses concise and referenced, avoiding unnecessary detail.

Requirements by Application Types: Biologics, NCEs, and Generics

While the eCTD framework is standardised, submission requirements differ by application type:

• Biologics licence applications often require additional quality and stability data. They also tend to generate more HSA queries.
• New drug applications typically demand extensive clinical and non-clinical data.
• Generic drug applications usually require bioequivalence studies and reduced content in Modules 4 and 5.

Customisation within the eCTD framework is therefore essential. While the overall structure remains the same, tailoring content to application type ensures compliance and smoother reviews.

Anticipating Future Trends in eCTD Submissions

Globally, regulatory authorities are moving towards eCTD v4.0, which promises greater interoperability across regions. 

In Singapore, the HSA is steadily advancing its digital capabilities. The agency has announced that its eCTD system will be available for test submissions in Q3/Q4 2025, with the official launch date for actual implementation to be confirmed at a later stage. Additionally, the HSA has clarified that all eCTD submissions must be prepared in alignment with International Council for Harmonisation (ICH) specifications to ensure consistency with global standards.

As such, companies must take a proactive approach. By upgrading software and aligning systems with HSA and ICH standards, you reduce the risk of disruption when the system goes live. Early preparation also positions your company for a smoother adoption of future regional and global initiatives.

Future-Proofing Your Submissions with Smarter Strategies

In Singapore, the eCTD provides pharmaceutical companies with a more efficient and structured route to regulatory approval. However, achieving success depends on more than adopting the format. It requires meticulous technical accuracy, strong regulatory expertise, and disciplined lifecycle management.

This is where The Reg Consultants (TRC) can make a difference. Our team provides end-to-end support, from compiling and validating dossiers to managing lifecycle updates in line with HSA requirements. We help companies minimise risks, streamline submissions, and stay ahead of evolving eCTD standards.

Have any questions or want to learn more? Get in touch with us today.

• Share This Article:

---